CD8A and cancer: Although type and degree of immunosuppression can vary substantially among heterogeneous patient groups, there is mounting evidence that patients with cancer do not develop as much humoral immunity as non-cancer subjects and may remain contagious and able to spread SARS CoV2 for several months.6 Yet, recent data suggest a role of CD8+T-cell response that might provide protection in patients with cancer even in the setting of defective humoral immunity.7